{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T07:09:10Z","timestamp":1722928150293},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2012,6,22]],"date-time":"2012-06-22T00:00:00Z","timestamp":1340323200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Radiol"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1007\/s00247-012-2440-0","type":"journal-article","created":{"date-parts":[[2012,6,21]],"date-time":"2012-06-21T18:54:37Z","timestamp":1340304877000},"page":"1218-1222","source":"Crossref","is-referenced-by-count":12,"title":["Marrow signal changes observed in follow-up whole-body MRI studies in children and young adults with neurofibromatosis type 1 treated with imatinib mesylate (Gleevec) for plexiform neurofibromas"],"prefix":"10.1007","volume":"42","author":[{"given":"Boaz","family":"Karmazyn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mervyn D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel Gregory","family":"Jennings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kent A.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,6,22]]},"reference":[{"key":"2440_CR1","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1532\/IJH97.04054","volume":"79","author":"G Borthakur","year":"2004","unstructured":"Borthakur G, Cortes JE (2004) Imatinib mesylate in the treatment of chronic myelogenous leukemia. Int J Hematol 79:411\u2013419","journal-title":"Int J Hematol"},{"key":"2440_CR2","doi-asserted-by":"crossref","first-page":"805","DOI":"10.2165\/00003495-200767050-00012","volume":"67","author":"MA Siddiqui","year":"2007","unstructured":"Siddiqui MA, Scott LJ (2007) Imatinib: a review of its use in the management of gastrointestinal stromal tumours. Drugs 67:805\u2013820","journal-title":"Drugs"},{"key":"2440_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/GIM.0b013e3181bf15e3","volume":"12","author":"K Jett","year":"2010","unstructured":"Jett K, Friedman JM (2010) Clinical and genetic aspects of neurofibromatosis 1. Genet Med 12:1\u201311","journal-title":"Genet Med"},{"key":"2440_CR4","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1002\/(SICI)1097-0142(19970601)79:11<2125::AID-CNCR9>3.0.CO;2-N","volume":"79","author":"ME Zoller","year":"1997","unstructured":"Zoller ME, Rembeck B, Oden A et al (1997) Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer 79:2125\u20132131","journal-title":"Cancer"},{"key":"2440_CR5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/jmg.39.5.311","volume":"39","author":"DG Evans","year":"2002","unstructured":"Evans DG, Baser ME, McGaughran J et al (2002) Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 39:311\u2013314","journal-title":"J Med Genet"},{"key":"2440_CR6","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.cell.2008.08.041","volume":"135","author":"FC Yang","year":"2008","unstructured":"Yang FC, Ingram DA, Chen S et al (2008) Nf1-dependent tumors require a microenvironment containing Nf1+\/\u2013 and c-kit-dependent bone marrow. Cell 135:437\u2013448","journal-title":"Cell"},{"key":"2440_CR7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11060-009-0049-4","volume":"98","author":"M Demestre","year":"2010","unstructured":"Demestre M, Herzberg J, Holtkamp N et al (2010) Imatinib mesylate (Glivec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft model. J Neurooncol 98:11\u201319","journal-title":"J Neurooncol"},{"key":"2440_CR8","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2147\/OPTH.S8521","volume":"4","author":"CM McClelland","year":"2010","unstructured":"McClelland CM, Harocopos GJ, Custer PL (2010) Periorbital edema secondary to imatinib mesylate. Clin Ophthalmol 4:427\u2013431","journal-title":"Clin Ophthalmol"},{"key":"2440_CR9","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/archopht.125.7.985","volume":"125","author":"JS Larson","year":"2007","unstructured":"Larson JS, Bergstrom LK, Cameron JD et al (2007) Severe periorbital edema secondary to imatinib mesylate for chronic myelogenous leukemia. Arch Ophthalmol 125:985\u2013986","journal-title":"Arch Ophthalmol"},{"key":"2440_CR10","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/cncr.10729","volume":"95","author":"B Esmaeli","year":"2002","unstructured":"Esmaeli B, Prieto VG, Butler CE et al (2002) Severe periorbital edema secondary to STI571 (Gleevec). Cancer 95:881\u2013887","journal-title":"Cancer"},{"key":"2440_CR11","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1067\/mjd.2003.44","volume":"48","author":"L Valeyrie","year":"2003","unstructured":"Valeyrie L, Bastuji-Garin S, Revuz J et al (2003) Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol 48:201\u2013206","journal-title":"J Am Acad Dermatol"},{"key":"2440_CR12","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11523-009-0110-4","volume":"4","author":"K Kelly","year":"2009","unstructured":"Kelly K, Swords R, Mahalingam D et al (2009) Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors. Target Oncol 4:99\u2013105","journal-title":"Target Oncol"},{"key":"2440_CR13","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00256-007-0344-0","volume":"36","author":"D Vanel","year":"2007","unstructured":"Vanel D, Bonvalot S, Pechoux CL et al (2007) Imatinib-induced bone marrow necrosis detected on MRI examination and mimicking bone metastases. Skeletal Radiol 36:895\u2013898","journal-title":"Skeletal Radiol"},{"key":"2440_CR14","first-page":"109","volume":"89","author":"T Tamura","year":"2004","unstructured":"Tamura T, Tasaka T, Fujimoto M et al (2004) Massive bone marrow necrosis in a patient with chronic myelocytic leukemia following imatinib mesylate therapy. Haematologica 89:109\u2013110","journal-title":"Haematologica"},{"key":"2440_CR15","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa051140","volume":"354","author":"E Berman","year":"2006","unstructured":"Berman E, Nicolaides M, Maki RG et al (2006) Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 354:2006\u20132013","journal-title":"N Engl J Med"},{"key":"2440_CR16","first-page":"2929","volume":"61","author":"K Pietras","year":"2001","unstructured":"Pietras K, Ostman A, Sjoquist M et al (2001) Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 61:2929\u20132934","journal-title":"Cancer Res"},{"key":"2440_CR17","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1148\/radiol.10100252","volume":"257","author":"AA Bankier","year":"2010","unstructured":"Bankier AA, Levine D, Halpern EF et al (2010) Consensus interpretation in imaging research: is there a better way? Radiology 257:14\u201317","journal-title":"Radiology"}],"container-title":["Pediatric Radiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00247-012-2440-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00247-012-2440-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00247-012-2440-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T10:35:59Z","timestamp":1558694159000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00247-012-2440-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,22]]},"references-count":17,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["2440"],"URL":"https:\/\/doi.org\/10.1007\/s00247-012-2440-0","relation":{},"ISSN":["0301-0449","1432-1998"],"issn-type":[{"value":"0301-0449","type":"print"},{"value":"1432-1998","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,22]]}}}